A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT04271514 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: RPT193
DRUG: Placebo

Sponsor

RAPT Therapeutics, Inc.